Please login to the form below

Not currently logged in


This page shows the latest Immutep news and features for those working in and with pharma, biotech and healthcare.

Immutep slumps on latest efti data in breast cancer

Immutep slumps on latest efti data in breast cancer

Analyst Dr Chris Redhead at Goetzpartners said the outcomes was a “substantial setback” for Immutep, but doesn’t mean that efti is dead. ... Immutep will need to keep its foot on the gas if it hopes to keep pace with some larger, deep-pocketed

Latest news

  • Immutep spikes on trial of its LAG-3 drug with Keytruda Immutep spikes on trial of its LAG-3 drug with Keytruda

    Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... Immutep also has a phase 2b trial of efti ongoing

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...